Combined data from Studies CL-QRX003-002 and CL-QRX003-003 is anticipated to provide QRX003 with the broadest possible label ...

Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone ...

Short interest in Quoin Pharmaceuticals Ltd (NASDAQ:QNRX) increased during the last reporting period, rising from 12.51K to 19.18K. This put 0.1% of the company's publicly available shares short.